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Abstract Because of numerous indications and high avail-
ability, non-steroidal anti-inflammatory drugs (NSAIDs) are
among themost commonly prescribed and usedmedicines in
the world. However, long-term therapy with and improper
use of NSAIDs may lead to gastrointestinal damage.
Therefore, improving the therapeutic index of the existing
drugs has become a priority over the past decades. Consid-
erable attention in the field has been concentrated on metal
complexes of non-steroidal anti-inflammatory drugs. The
aim of this study is to evaluate the effect of complexation
with zinc on the anti-inflammatory and ulcerogenic effects of
ibuprofen and naproxen after single and triple intragastric
administration to rats. The anti-inflammatory effect was
assessed in carrageenan-induced inflammatory edema in the
hind paw of male albino Wistar rats. The mucosal lesions
were inspected and evaluated for gross pathology. Single
administration of both the investigated complexes, namely
zinc–ibuprofen and zinc–naproxen (20 mg/kg equivalent to
ibuprofen and naproxen, respectively) and their parent drugs
and physical mixtures with zinc hydroaspartate (ZHA doses:
16.05 and 14.37 mg/kg), caused a significant reduction of the
edema after the same time from the carrageenan injection in
comparison to the control groups. However, no statistically
significant differences between the investigated drugs were
observed after their single administration. The mean ulcer-
ation score for the mixture of ibuprofen and ZHA was
statistically lower than the mean score achieved in rats after
treatment with ibuprofen alone. On the other hand, triple
intragastric administration of the ZHA–ibuprofen and ZHA–
naproxen combination showed substantial enhancement of
the anti-inflammatory activity against control groups, as well
as against the parent NSAIDs. The most potent anti-inflam-
matory activity was demonstrated after 2 h from the
carrageenan injection in animals receiving ZHA together
with naproxen. The edema growth was reduced in these
animals by 80.9% as compared to the control group. This
result was significantly higher than the results achieved in
animals receiving zinc–naproxen (50.2%) or naproxen alone
(47.9%). Both NSAID complexes with zinc and mixtures
with ZHA alleviated ulcerations caused by parent NSAIDs;
however, the mixtures of both ibuprofen and naproxen with
ZHA after triple administration were the least damaging. In
view of the above results, zinc supplementation during
NSAID therapy may have a beneficial effect on ulcer pre-
vention and healing by reducing the effective dose of the
parent drug and increasing its potency.
Keywords Zinc  NSAIDs  Zinc complexes 
Anti-inflammatory activity  Gastric ulcers
Introduction
Since the ancient times, medicines derived from willow trees
and other salicylate-rich plants have been used for relieving
pain and reducing fever.However, itwas not until the isolation
of salicin in 1828 and the subsequent development of the drug
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aspirin in 1899 that pharmacologists’ interest in non-steroidal
anti-inflammatory drugs (NSAIDs)was awakened. Currently,
because of numerous indications and high availability,
NSAIDs are among the most commonly prescribed and used
medicines in the world (Patrono andRocca 2009;Markiewicz
and Pasenkiewicz-Gierula 2011). The primary mechanism of
action of NSAIDs is the inhibition of cyclooxygenase (COX)
enzymes, leading to reduced prostaglandin biosynthesis,
which determines their versatile effectiveness as analgesics,
antipyretics, and anti-inflammatory agents (Capone et al.
2007).Unfortunately, thismechanism also largely contributes
to the gastrointestinal (GI) toxicity of NSAIDs (Watanabe
et al. 2002; Wallace 2008). The most common side effects
during NSAID therapy include gastric and duodenal ulcera-
tions and bleedings. Further, the small intestine and the colon
are exposed to numerous complications including bleeding,
perforation, stricture, and chronic problems, such as iron
deficiency anemia and protein loss (Sostres et al. 2010; Park
et al. 2011). The inhibited synthesis of cytoprotective pros-
taglandins (PGE2 and PGI2) increases gastric acid secretion,
reduces mucus synthesis and bicarbonate secretion, and
impairs gastric mucosal blood flow. Consequently, gastric
mucosal defense and healing are severely impaired (Wallace
2008). Irrespectiveofhow remarkable the correlation between
the suppressed PG synthesis and the occurrence of ulcers is,
the pathogenesis of NSAID-induced ulcerations is complex
(Lim et al. 2009; Musumba et al. 2009). Recent findings have
shown that factors such as nitric oxide and hydrogen sulfide,
growth factors, neuropeptides, hormones, and stress proteins
act in concert with PGs in maintaining the gastric mucosal
defense. Moreover, the direct local effect of acidic NSAIDs
plays a significant role in ulcer formation. Factors contributing
to NSAID-induced GI toxicity are summarized in Fig. 1.
Recent approaches to reduce GI side effects during
NSAID therapy are based on the introduction of potential
novel therapeutics, such as nitric oxide (NO) or hydrogen
sulfide (H2S)-complexed NSAIDs, lipid-modified NSAIDs,
andmetal-complexedNSAIDs (Lim et al. 2009; Fiorucci and
Distrutti 2011). The transport of organic ligands into the cells
can be facilitated by the formation of metal complexes
(Sharma et al. 2003;AbuAli et al. 2015). Therefore,NSAIDs
complexation with metals, particularly copper and zinc, may
yield measurable benefits, i.e., reduce the effective dose of
the parent drug and increase potency, while limiting adverse
reactions, expanding indications for use, or increasing the
selectivity toward certain diseases (Dillon et al. 2003).
Zinc has been shown to modulate immune response and
may be considered an important agent with anti-inflamma-
tory and antioxidant activity (Jarosz et al. 2017). The role of
zinc in accelerating the healing of wounds, including ulcers,
is also recognized worldwide (Lansdown et al. 2007). In
1994, the first gastroprotective chelate of zinc and L-carno-
sine (polaprezinc, PZ) was introduced into the Japanese
market. Although this drug has already been in use for more
than 20 years, its mechanism of action remains not fully
understood. The gastroprotection exhibited by PZ has been
attributed to its antioxidant activity, the stabilizing effect on
membranes, the inducing effect on mucus and endogenous
PG synthesis, and the stimulating effect on heat shock pro-
teins HSP 70 and HSP 32 [heme oxygenase (HO)-1],
recognized as potential gastroprotective agents (Shimada
et al. 1999; Naito et al. 2001; Ueda et al. 2009; Opoka et al.
2010). Some of the studies have shown the key role played by
zinc in the inhibition of indomethacin-induced apoptosis of
gastric mucosa by inhibiting the activity of caspase-3 (the
same study did not confirm the anti-apoptotic properties of
carnosine) (Fuji et al. 2000). It was also demonstrated that PZ
inhibits the expression of mRNA for TNF-a, reduces its
levels in the gastric mucosa, and inhibits the activation of
NF-kB (Shimada et al. 1999; Naito et al. 2001). Moreover,
zinc sulfate has been found to prevent indomethacin-induced
changes in the content of mucosal lipids and sugars followed
by the translocation of luminal bacteria (Sivalingam et al.
2011). In accordance to recently conducted research, treat-
ment with zinc hydroaspartate (ZHA) stimulates gastric
microcirculation, significantly reduces gastric secretion, and
increases the plasma gastrin level. The administration of
ZHA after the induction of ulcers in animals (ZHA dose:
65 mg/kg daily) resulted in an increase in the zinc ion levels
in the gastric juice and the ulcerated area, which significantly
accelerated the healing process at day 7 upon ulcer induction
(Opoka et al. 2010).
The anti-inflammatory, antioxidant, and wound healing
properties of zinc became the basis for the idea of its
complexation with NSAIDs. Selected results of the thus far
tested complexes are summarized in Table 1.
The study’s aim was to evaluate the effect of com-
plexation with zinc on the anti-inflammatory and
ulcerogenic effects of ibuprofen and naproxen after single
and triple intragastric administration to rats.
Materials and methods
Materials
Animals
Male albino Wistar rats, weighing between 155 and 205 g,
were used for the anti-inflammatory tests. The animals were
housed and fed in a laboratory and kept at a constant temper-
ature of 22 C under standard conditions (a 12:12-h L:D cycle,
standardpellet diet, tapwater). Treatment of laboratory animals
in the present study was in full accordance with the respective
Polish and European regulations date and file or reference
number of Ethic’s Committee approval of the animal study.
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Chemicals
Zinc–ibuprofen and zinc–naproxen complexes were syn-
thesized in the Department of Bioorganic Chemistry, Chair
of Organic Chemistry, Faculty of Pharmacy, Jagiellonian
University Medical College. Both the synthesized com-
plexes, as well as ibuprofen (Sigma-Aldrich, Germany),
naproxen (Sigma-Aldrich, Germany), and ZHA (Farmapol,
Poznań) for intragastric administration were finely pow-
dered and suspended/dissolved ex tempore in distilled
water.
Methods
Preparation of zinc complexes of ibuprofen
and naproxen
Sodium hydroxide (0.1 mol NaOH) was dissolved in the
smallest amount of H2O. To this solution, 0.1 mol of
naproxen was added with constant stirring. Complete dis-
solution meant sodium naproxen formation. Then,
0.07 mol of ZnSO47H2O dissolved in the smallest amount
of H2O was added with constant stirring. The precipitated
zinc–naproxen complex was filtered and washed with
NaHCO3 and then with H2O to remove the unreacted
naproxen. The obtained filtrate was acidified to recover the
unreacted naproxen. The same procedure was used for
obtaining the zinc–ibuprofen complex.
Determination of anti-inflammatory activity of the
investigated compounds using the carrageenan-induced
hind paw edema test.
Animals that fasted for 24 h before the experiment were
used in the hind paw oedema test. Rats were randomly
divided into five groups, each with seven individuals. The
experiments were conducted according to the approved
scheme (Table 2). The tested compounds were adminis-
tered intragastrically to the fasted rats having free access to
drinking water. After 1 h, to produce inflammation, 0.1 mL
of 1% carrageenan solution in water was injected into the
NSAID-induced GI toxicity
Systemic effects
PG-independent
♦ ↑ synthesis of leukotriens 
(LTB4) →
↑ leukocyte adherence,
stimulation of inflammatory 
processes, ↑ susceptibility to 
injury
♦ iNOS activation/ cNOS 
inactivation; ↓ H2S production 
→
↓ gastric mucosal blood flow, ↑ 
leukocyte adherence, 
↓ angiogenesis, → 
stimulation of inflammatory 
processes, ↑ susceptibility to 
injury
PG-dependent
COX-1 inhibition:
♦ ↓ gastric mucosal blood flow
♦ ↓ mucus, phospholipids, 
bicarbonate
♦ ↑ acid
♦ ↑ permeability
stimulation of inflammatory 
processes, ↑ susceptibility to 
injury
COX-2 inhibition:
♦ ↓ release of growth factors → 
↓ epithelial cell proliferation, 
↓ angiogenesis
♦ ↑ leukocyte adherence →
stimulation of inflammatory 
processes, ↑ susceptibility to 
injury
Topical effects
♦ „ion trapping” in gastric 
epithelial cells → uncoupling 
of mitochondrial oxidative 
phosphorylation, inhibition of 
the electron transport chain, ↑ 
ROS → apoptosis, necrosis →
mucosal injuries, erosions
♦ interaction with extracellular 
and membrane phospholipids 
→ 
↓ hydrophobicity, changes in 
membrane thickness, fluidity, 
bending stiffness and pore 
formation, 
↑ permeability,
↑ susceptibility to injury
♦ ↓ EGF  binding to its receptor 
→ 
↓ epithelial repair
Fig. 1 Mechanisms of NSAID-induced GI toxicity can be divided into topical and systemic effects, and the latter may be prostaglandin-
dependent through COX inhibition or prostaglandin-independent (Wallace 2008; Lim et al. 2009; Musumba et al. 2009)
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hind paw subplantar tissue of rats, according to the modi-
fied method of Winter et al. (1962). The development of
paw edema was measured plethysmographically (Ugo
Basile, Italy). Paw diameters were measured and recorded
prior to the carrageenan injection and after 1, 2, and 3 h,
while the percentage of the edema inhibition was calcu-
lated according to the following formula:
Oedema inhibition % ¼ ðN  N
0  100Þ
N
;
where N denotes the paw diameters measured 1, 2, and
3 h after the carrageenan injection to the control group—
paw diameters at the beginning. N0 represents the paw
diameters measured 1, 2, and 3 h after the carrageenan
injection to the test groups—paw diameters at the
beginning.
Irritant action on the gastric mucosa according
to Komatsu
The ulcerogenic effect was determined by the method of
Komatsu et al. (1973). The tested compounds were
administered to the fasted rats having free access to
drinking water. Twenty-four hours after the administra-
tion of the compounds, the rats were killed, and their
stomachs were removed and after incision along the
lesser curvature, rinsed with a tap soaked in warm
(37 C) saline, spread on a cork board, and pinned down.
The mucosa of the glandular part of the stomach was
inspected using a binocular microscope (tenfold magni-
fication). The stomachs were photographed. The mucosal
lesions were evaluated using a 0–5 point scale (0: no
lesions, 1: erythema, 2: hemorrhagic streaks, 3: small
ulcers, 4: large ulcers, 5: perforation).
Statistical analysis
In the carrageenan-induced hind paw edema test, the
obtained data were evaluated by a two-way analysis of
variance (two-way ANOVA), followed by Bonferroni’s
multiple comparison test; p\ 0.05 was considered signif-
icant. In ulcerogenic activity the test data were evaluated
by a two-way analysis of variance (two-way ANOVA),
followed by Tukey’s test; p\ 0.05 was considered
significant.
Results and discussion
The results of the carrageenan-induced hind paw edema
test of Zn–ibuprofen and Zn–naproxen are shown in Figs. 2
and 3 and the percentage of edema inhibition are presented
in Tables 3 and 4, respectively.
Single intragastric administration of ZHA alone in doses
of 16.05 and 14.37 mg/kg did not significantly influence
the rat hind paw edema. This result may be attributed to the
low doses of zinc used (zinc ions in the amount of 3.17 and
2.84 mg/kg). In contrast, triple intragastric administration
of the same low doses of zinc significantly reduced the
edema 2 h after the carrageenan injection by 36.6% (ZHA
dose: 16.05 mg/kg) and after 2 and 3 h, by 27.5 and 21.2%,
respectively (ZHA dose: 14.37 mg/kg). Zinc exerts its anti-
inflammatory and antioxidant activity through several
acute and chronic mechanisms (Powell 2000). It acts by
antagonizing transition metal-catalyzed reactions, stabiliz-
ing the protein sulfhydryls, activating antioxidant proteins,
enzymes, and metallothioneins. Moreover, zinc decreases
NF-jB activation and its target genes, such as TNF-a and
IL-1b, and increases the gene expression of A20 and
Table 2 Scheme of the experiments
Single intragastric administration
1 9 p.o.
Triple intragastric administration
3 9 p.o.
Zn-ibuprofen
n = 7
1. Control (water p.o.)
2. ZHA 16.05 mg/kg in water (zinc 3.17 mg/kg)
3. Ibuprofen 20 mg/kg in water
4. Zn-ibuprofen 24.93 mg/kg in water (ibuprofen 20 mg/kg and zinc
3.17 mg/kg)
5. ZHA 16.05 mg/kg ? Ibuprofen 20 mg/kg in water
Rats divided into five groups (according to the
scheme of single administration) received
investigated compounds for three consecutive
days. Prior to third administration rats were fasted
for 24 h. The hind paw edema test was performed
on fasted rats on day 3. Rats were killed on day 4
Zn-naproxen
n = 7
1. Control (water p.o.)
2. ZHA 14.37 mg/kg in water (zinc 2.84 mg/kg)
3. Naproxen 20 mg/kg in water
4. Zn-naproxen 24.41 mg/kg in water (ibuprofen 20 mg/kg and zinc
2.84 mg/kg)
5. ZHA 14.37 mg/kg ? Naproxen 20 mg/kg in water
Rats divided into five groups (according to the
scheme of single administration) received
investigated compounds for three consecutive
days. Prior to third administration rats were fasted
for 24 h. The hind paw edema test was performed
on fasted rats on day 3. Rats were killed on day 4
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PPAR-a, the two zinc finger proteins with anti-inflamma-
tory properties (Jarosz et al. 2017). Repeated
administration of low doses of ZHA in both experiments
did confirm the anti-inflammatory activity exerted by zinc
ions.
Anti-inflammatory studies using carrageenan-induced
hind paw edema showed differences in the anti-inflam-
matory activity of the parent NSAIDs, their zinc
complexes, and the physical mixtures of NSAIDs and
ZHA. Single administration of both investigated com-
plexes, zinc–ibuprofen and zinc–naproxen, as well as their
parent drugs and physical mixtures with ZHA, caused
statistically significant reduction of the edema after the
same time from the carrageenan injection in comparison to
the control groups. The highest percentage of edema
inhibition was observed for Zn–NSAID complexes; zinc–
ibuprofen reduced the edema after 2 and 3 h by 55.5 and
39.9%, whereas zinc–naproxen reduced the edema after 2
and 3 h by 60.4 and 66.0%, respectively. No statistically
significant differences between the investigated drugs were
observed after their single intragastric administration.
Only 3-day experiments revealed significant differences
in the anti-inflammatory activity between the investigated
compounds. The mixture of ibuprofen and ZHA signifi-
cantly reduced the edema after 1 and 3 h from the
carrageenan injection in comparison to ibuprofen alone
(61.3 and 73.5 vs. 12.4 and 50.5%, respectively). The
differences between zinc–ibuprofen and the mixture of
ZHA and ibuprofen were insignificant; however, the
achieved percentage of edema inhibition was higher for the
mixture. A similar trend was observed for the triple intra-
gastric administration of naproxen, its complex with zinc,
and the physical mixture with ZHA. The most potent anti-
inflammatory activity was demonstrated after 2 h from the
carrageenan injection in animals receiving ZHA together
with naproxen. The edema development was reduced in
Fig. 2 Results of carrageenan-induced hind paw edema test for zinc
hydroaspartate (ZHA), ibuprofen, zinc–ibuprofen, and physical
mixture of ZHA and ibuprofen after their single (a) and triple
(b) administration. Data expressed as the mean ± SD; evaluated by a
two-way analysis of variance (two-way ANOVA), followed by
Bonferroni’s multiple comparison test; ap\ 0.05, bp\ 0.01,
cp\ 0.001, and dp\ 0.0001; n = 6–7
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these animals by 80.9% as compared to the control group.
This result was significantly higher than the results
achieved in animals receiving zinc–naproxen (50.2%) or
naproxen alone (47.9%). The mixture remarkably reduced
the edema also after 3 h from the carrageenan injection (the
result was significantly higher than the result obtained in
the naproxen group). Repeated intragastric administration
of the ZHA–ibuprofen and ZHA–naproxen combinations
showed a substantial enhancement of the anti-inflammatory
activity against ibuprofen and naproxen, respectively.
These results are in line with the ulcerogenic effects
determined according to the method established by
Komatsu et al. (1973). The results of irritant action on the
gastric mucosa are listed in Tables 5 and 6. The ulceration
scores for the control and the ZHA animals were equal to
zero and are not included in the tables. Both NSAID
complexes with zinc and the mixtures with ZHA alleviated
ulcerations caused by the parent NSAIDs. The differences
in the ulcerogenic potential between the complexes and the
mixtures were negligible; however, the mixtures of both
ibuprofen and naproxen with ZHA after the triple admin-
istration were the least damaging. Moreover, the mean
ulceration score for the mixture of ibuprofen and ZHA after
the single administration was significantly lower than the
mean score achieved in rats after treatment with ibuprofen
alone. To the best of our knowledge, this is the first report
comparing the anti-inflammatory and ulcerogenic effects of
the zinc–ibuprofen and zinc–naproxen complexes after
their single and triple administration to rats. Furthermore,
we collated these effects with the results obtained after the
administration of not only the parent NSAIDs but also their
mixtures with ZHA and ZHA alone.
The search for more effective and less toxic anti-in-
flammatory drug treatments continues. Several earlier
Fig. 3 Results of carrageenan-induced hind paw edema test for zinc
hydroaspartate (ZHA), naproxen, zinc–naproxen, and physical mix-
ture of ZHA and naproxen after their single (a) and triple
(b) administration. Data expressed as the mean ± SD; evaluated by
a two-way analysis of variance (two-way ANOVA), followed by
Bonferroni’s multiple comparison test; ap\ 0.05, bp\ 0.01,
cp\ 0.001, and dp\ 0.0001; n = 6–7
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studies were designed to characterize transition metal
complexes of NSAIDs and evaluate their anti-inflamma-
tory, antioxidant, antibacterial, or ulcerogenic activity. The
results of the anti-inflammatory and ulcerogenic potential
of the thus far tested zinc complexes of NSAIDs are
summarized in Table 1. In the study by Singla and Wad-
hwa (1995), the zinc–indomethacin complex was three
times more potent as an anti-inflammatory agent than pure
indomethacin. However, no statistically significant differ-
ence in the lesion index between the complex and an
equivalent amount of indomethacin was observed. The
authors seek the cause of such observation in the extensive
enterohepatic circulation of indomethacin in the bile, as
well as in the very small content of zinc (0.9 mg/kg)
present in the zinc–indomethacin complex. Consequently,
the contribution of zinc toward an increase in the anti-
inflammatory potency seems to be minimal, and this
increase is attributed by the authors mainly to a greater rate
and extent of absorption of the indomethacin from the
complexed form. On the other hand, studies by Santos et al.
(2004), Jain et al. (1999), and Tagliati et al. (1999)
demonstrated that the anti-inflammatory activity of
diclofenac, naproxen, and piroxicam were not changed by
complexing with zinc, whereas a reduction of the severity
of lesions was observed in all the three experiments. In
contrast to the results achieved by Jain et al. (1999), other
group have shown a statistically significant difference in
the anti-inflammatory activity of naproxen and its zinc
complex (Sharma et al. 2003). Furthermore, a significant
reduction in the lesion index of the zinc complex was
observed as compared to naproxen. Nevertheless, the
selected doses of naproxen and its zinc complex were
considerably higher (100 mg/kg equivalent to naproxen)
than doses tested by other researchers.
In contrast to earlier opinions that the metal ion com-
plexation of organic ligands facilitates their transport into
the cells, Tagliati et al. (1999) observed that the absorption
of the zinc–piroxicam complex was slower than the
absorption of the free drug. In the opinion of the authors,
the slower, progressive absorption pattern may contribute
to the reduction of adverse effects in a manner similar to
slow-release pharmaceutical formulations. At the same
time, no statistically significant differences in the anti-in-
flammatory activity between piroxicam and zinc–
piroxicam were observed; paw increases were similar in
value after 1, 2, and 5 h from the carrageenan injection. We
suppose that zinc may have contributed to the anti-in-
flammatory effect exerted by zinc–piroxicam during first
2 h after the carrageenan injection, as anti-edematous
effects of both the complex and piroxicam were similar and
Table 3 Results of hind paw oedema test expressed as a percentage
Percent of oedema inhibition
1st hour 2nd hour 3rd hour
1 9 p.o.
ZHA 7.0 16.7 1.5
Ibuprofen 22.7 39.2b 35.1c
Zn-ibuprofen 31.8 55.5d 39.9d
ZHA ? Ibuprofen 29.6 50.7d 27.9b
3 9 p.o.
ZHA 22.5 36.6d 10.4
Ibuprofen 12.4 51.5d 50.5d
Zn-ibuprofen 29.9 58.2d 54.1d
ZHA ? Ibuprofen 61.3b 74.4d 73.5d
Bold font indicates results that were statistically significant vs. the
control: a p\ 0.05, b p\ 0.01, c p\ 0.001, and d p\ 0.0001. Bold
italic font indicates results that were statistically significant vs. the
parent NSAID
Table 4 Results expressed as a percentage
Percent of oedema inhibition
1st hour 2nd hour 3rd hour
1 9 p.o.
ZHA 19.4 16.7 14.1
Naproxen 42.5b 44.6d 54.1d
Zn-naproxen 65.6d 60.4d 66.0d
ZHA ? Naproxen 53.7c 52.2d 60.7d
3 9 p.o.
ZHA 6.9 27.5a 21.2b
Naproxen 13.3 47.9d 49.2d
Zn-naproxen 11.8 50.2d 63.4d
ZHA ? Naproxen 25.1 80.9d 73.1d
Bold font indicates results that were statistically significant vs. the
control: a p\ 0.05, b p\ 0.01, c p\ 0.001, and d p\ 0.0001. Bold
italic font indicates results that were statistically significant vs. the
parent NSAID
Table 5 Irritant action on the gastric mucosa according to Komatsu
Ulcerogenic effect
Single intragastric
administration
1 9 p.o.
Triple intragastric
administration
3 9 p.o.
Ibuprofen 1.67 ± 0.11 1.58 ± 0.08
Zn-ibuprofen 1.08 ± 0.30 1.33 ± 0.11
ZHA ? Ibuprofen 1.00a ± 0.13 1.00 ± 0.22
The mucosal lesions were evaluated using a 0–5 point scale (0: no
lesions, 1: erythema, 2: hemorrhagic streaks, 3: small ulcers, 4: large
ulcers, 5: perforation). Data evaluated by a two-way analysis of
variance (two-way ANOVA), followed by Tukey’s test. Each result is
an average of six rates ± SEM. Bold font indicates results that were
statistically significant vs. the parent NSAID: a p\ 0.05
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the plasma piroxicam levels were lower after the admin-
istration of the complex than after that of piroxicam.
In our experiments, the doses of the investigated
NSAIDs and their zinc complexes were selected on the
basis of the earlier dose-dependence studies (our unpub-
lished data). The dosage and the salt form of zinc were
chosen with respect to previous research. For example, in
the study by Sharma et al. (2003), different doses of
naproxen and its zinc complex were used for evaluating the
anti-inflammatory and ulcerogenic potential of the inves-
tigated compounds; i.e., naproxen and zinc–naproxen in the
hind paw edema test were used in the dose of or equivalent
to 100 mg/kg, whereas the ulcerogenic effect was deter-
mined for a dose of 29 mg/kg administered to rats twice a
day over a 2-day period. Further, the dose of zinc in the
form of zinc sulfate was remarkably higher (fivefold
higher) than doses applied in our experiments; the single
dose of zinc ions used in the hind paw edema test was
15 mg/kg. The authors perceived the reasons for the
damage to the gastric mucosa caused by the mixture of
naproxen and zinc sulfate to be the ulcerogenic effect of
naproxen along with the corrosive effects of an overdosage
of zinc sulfate on the gastric mucosa, which, by its con-
version to zinc chloride in the stomach, is highly astringent.
Therefore, in our experiments, instead of inorganic zinc
salts, we administered to the rats ZHA, which was proven
by Opoka et al. (2010) to possess gastroprotective poten-
tial. Moreover, as the standard rat diet contains a sufficient
amount of zinc to maintain the animals’ health and no
pathological conditions were induced in rats before the
drugs’ administration, we reduced the risk of overdosing
zinc ions by selecting low doses of the zinc salt. To
facilitate comparisons, we used two uneven doses of zinc in
the form of ZHA (16.05 and 14.37 mg/kg), which were
equivalent to the doses of zinc contained in the zinc
complexes.
According to Mohod and Bodhankar (2013), naproxen
administered at a dose of 30 mg/kg p.o. consecutively for
3 days clearly showed a gastric antral ulcer and dramati-
cally decreased superoxide dismutase (SOD), glutathione
(GSH), and nitric oxide (NO), as well as increased
malondialdehyde (MDA), myeloperoxidase (MPO), and
histamine in the rats’ stomachs. Researchers perceive the
major underlying factor of naproxen-induced gastric antral
ulceration in the generation of oxygen-free radicals and
lipid peroxidation. Moreover, other studies indicate the
significant role of enzymes such as SOD, catalase (CAT),
and glutathione peroxidase (GPx) in the defense against the
oxidative tissue damage of the gastric mucosa after the
administration of naproxen (Kim et al. 2005, 2014).
Moreover, in the rat model, the nuclear factor erythroid
2-related factor 2 (Nrf2) expression in the naproxen-in-
duced gastric ulcer group was lower than in the untreated
rats, suggesting that Nrf2 plays an important role in
naproxen-induced gastric ulceration and its subsequent
alleviation (Kim et al. 2014). Zinc is a co-factor of the
cytosolic and extracellular Zn/Cu SOD enzyme, which acts
as an ROS scavenger and contributes to the regulation of
neutrophil apoptosis and neutrophil-mediated tissue injury
(Yasui et al. 2005; Yasui and Baba 2006; Mariani et al.
2008). Moreover, zinc treatment to chlorpyriphos-intoxi-
cated animals elevated the levels of GSH, CAT, and
detoxifying glutathione-S-transferase (GST) (Goel et al.
2005). Nrf2, the critical transcription factor that regulates
the expression of genes encoding the above-mentioned
antioxidant and detoxifying molecules (GSH, SOD, and
GST) has been proven to be up-regulated by zinc (Zhao
et al. 2011; Smith and Loo 2012). In the view of the above
results, zinc supplementation during the NSAID therapy
seems fully reasoned.
The results of our study confirmed the advantage of the
use of the zinc complexes and the combination of NSAIDs
and ZHA over the parent drugs. The highest percentage of
edema inhibition after single administration was achieved
in rats receiving zinc–ibuprofen and zinc–naproxen,
whereas the most meaningful results after triple adminis-
tration were obtained for the physical mixtures of the
parent NSAIDs and ZHA. The explanation for this is not
simple. Certainly, zinc complexes and ZHA combinations
with NSAIDs exert an uneven local effect on the gastric
mucosa primarily because of the presence of a masked or
free carboxyl group of the parent drug. Moreover, the
differences in polarity, lipophilicity, and solubility pre-
sumably influence the absorption of the compounds from
the gastrointestinal tract. Furthermore, the prolonged
treatment may result in an adaptation of the gastric mucosa
to specific drugs or combination of drugs, as was already
suggested in the case of NSAIDs (Skeljo et al. 1992, 1996).
Finally, the repeated ZHA administration may induce/en-
hance the synthesis/release/secretion of specific factors
(proteins) involved in (anti)inflammatory processes
Table 6 Irritant action on the gastric mucosa according to Komatsu
Ulcerogenic effect
Single intragastric
administration
1 9 p.o.
Triple intragastric
administration
3 9 p.o.
Naproxen 1.92 ± 0.15 1.67 ± 0.17
Zn-naproxen 1.75 ± 0.11 1.50 ± 0.18
ZHA ? Naproxen 1.83 ± 0.11 1.42 ± 0.15
The mucosal lesions were evaluated using a five-point scale (0: no
lesions, 1: erythema, 2: punctiform ulcers, 3: small ulcers, 4: large
ulcers, 5: perforation). Data evaluated by a two-way analysis of
variance (two-way ANOVA), followed by Tukey’s test. Each result is
an average of six rates ± SEM
Evaluation of anti-inflammatory and ulcerogenic potential of zinc–ibuprofen and zinc… 661
123
(probably from the gastrointestinal tract). These issues
should be examined in future studies.
Moreover, note the role of zinc deficiency in gastro-
duodenal ulcerogenesis during NSAID treatment. A zinc
deficiency in the experimental animals amplified injuries
and retarded the healing of ulcers (Watanabe et al. 1995;
Lansdown et al. 2007). Studies revealed significantly
increased oxidative damage and decreased Nrf2 expression
in zinc-deficient mice (Zhao et al. 2011). Preparations
containing zinc accelerated the healing of ulcers in the
gastrointestinal tract, suppressed acid secretion, and
improved the production of the tissue levels of metalloth-
ionein, mucus, and endogenous protective PGE2 (Bulbena
et al. 1993; Tapiero and Tew 2003). According to the
World Health Organization (WHO), zinc deficiency is one
of the major life-threatening risk factors, particularly in
developing countries and in the aging community in the
industrial world (Eriksen et al. 2002). Moreover, impair-
ment of zinc absorption is a documented concern of the
long-term use of medications such as proton pump inhi-
bitors, which are very often prescribed together with
NSAIDs (Skrovanek 2014). Therefore, zinc supplementa-
tion may have an exceptionally beneficial effect on ulcer
prevention and healing if there is an underlying zinc defi-
ciency. The role of zinc supplementation during NSAID
treatment to zinc-deficient patients should be examined in
future studies.
Conclusions
A lot of research is concentrated on the search for an ideal
antiulcer drug, preferably of natural origin, which could be
given prophylactically or therapeutically to patients during
or after NSAID treatment. We chose the most frequently
used NSAIDs, ibuprofen and naproxen, to synthesize their
zinc complexes and determine their anti-inflammatory and
ulcerogenic potential. The results of the hind paw edema
test confirmed the validity of the combined use of zinc ions
together with NSAIDs. In the case of a single administra-
tion, the highest percentage of edema inhibition was
achieved in rats receiving zinc–ibuprofen and zinc–
naproxen, whereas in the case of triple administration, the
most meaningful results were obtained for the physical
mixtures of parent NSAIDs and ZHA. Both NSAID com-
plexes with zinc and their physical mixtures with ZHA
reduced the severity of lesions as compared to the parent
drugs. In the view of the above results, zinc supplemen-
tation during NSAID therapy may have a beneficial effect
on ulcer prevention and healing by reducing the effective
dose of the parent drug and increasing its potency. Nev-
ertheless, defining the precise mechanism of the anti-
inflammatory and gastroprotective effects induced by zinc
ions in a free or complexed form during the NSAID
treatment remains a topic for future research.
Acknowledgements The study was supported by the statutory funds
of the Faculty of Pharmacy, Jagiellonian University Medical College.
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted
use, distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were
made.
References
Abu Ali H, Fares H, Darawsheh M et al (2015) Synthesis,
characterization and biological activity of new mixed ligand
complexes of Zn(II) naproxen with nitrogen based ligands. Eur J
Med Chem 89:67–76. doi:10.1016/j.ejmech.2014.10.032
Bulbena O, Escolar G, Navarro C et al (1993) Gastroprotective effect
of zinc acexamate against damage induced by nonsteroidal
antiinflammatory drugs. A morphological study. Dig Dis Sci
38:730–739
Capone ML, Tacconelli S, Di Francesco L et al (2007) Pharmaco-
dynamic of cyclooxygenase inhibitors in humans. Prostaglandins
Other Lipid Mediat 82:85–94
Dillon CT, Hambley TW, Kennedy BJ et al (2003) Gastrointestinal
toxicity, antiinflammatory activity, and superoxide dismutase
activity of copper and zinc complexes of the antiinflammatory
drug indomethacin. Chem Res Toxicol 16:28–37. doi:10.1021/
tx020078o
Eriksen M, Ezzati M, Holck S et al (2002) The world health report
2002–Reducing Risks, Promoting Healthy Life. World Health
Organization. http://www.who.int/whr/2002/en/. Accessed 21
Apr 2017
Fiorucci S, Distrutti E (2011) COXIBs, CINODs and H(2)S-releasing
NSAIDs: current perspectives in the development of safer non
steroidal anti-inflammatory drugs. Curr Med Chem
18:3494–3505. doi:10.2174/092986711796642508
Fuji Y, Matsura T, Kai M et al (2000) Protection by polaprezinc, an
anti-ulcer drug, against indomethacin-induced apoptosis in rat
gastric mucosal cells. Jpn J Pharmacol 84:63–70. doi:10.1254/
jjp.84.63
Goel A, Dani V, Dhawan DK (2005) Protective effects of zinc on
lipid peroxidation, antioxidant enzymes and hepatic histoarchi-
tecture in chlorpyrifos-induced toxicity. Chem Biol Interact
156:131–140. doi:10.1016/j.cbi.2005.08.004
Jain NK, Singh A, Kulkarni SK (1999) Analgesic, anti-inflammatory
and ulcerogenic activity of a zinc–naproxen complex in mice and
rats. Pharm Pharmacol Commun 5:599–602. doi:10.1211/
146080899128734208
Jarosz M, Olbert M, Wyszogrodzka G et al (2017) Antioxidant and
anti-inflammatory effects of zinc. Zinc-dependent NF-jB sig-
naling. Inflammopharmacology. doi:10.1007/s10787-017-0309-4
Kim J-H, Kim Y-S, Song G-G et al (2005) Protective effect of
astaxanthin on naproxen-induced gastric antral ulceration in rats.
Eur J Pharmacol 514:53–59. doi:10.1016/j.ejphar.2005.03.034
Kim S-J, Min Kim J, Hee Shim S, Ihl Chang H (2014) Anthocyanins
accelerate the healing of naproxen-induced gastric ulcer in rats
by activating antioxidant enzymes via modulation of Nrf2.
J Funct Foods 7:569–579. doi:10.1016/j.jff.2013.12.028
662 M. Jarosz et al.
123
Komatsu T, Awata H, Sakai Y et al (1973) Additional data on an anti-
inflammatory agent, ID-955. Arzneimittelforschung 23:500–503
Lansdown ABG, Mirastschijski U, Stubbs N et al (2007) Zinc in
wound healing: theoretical, experimental, and clinical aspects.
Wound Repair Regen 15:2–16. doi:10.1111/j.1524-475X.2006.
00179.x
Lim YJ, Lee JS, Ku YS, Hahm KB (2009) Rescue strategies against
non-steroidal anti-inflammatory drug-induced gastroduodenal
damage. J Gastroenterol Hepatol 24:1169–1178
Mariani E, Mangialasche F, Feliziani FT et al (2008) Effects of zinc
supplementation on antioxidant enzyme activities in healthy old
subjects. Exp Gerontol 43:445–451. doi:10.1016/j.exger.2007.
10.012
Markiewicz M, Pasenkiewicz-Gierula M (2011) Comparative model
studies of gastric toxicity of nonsteroidal anti-inflammatory
drugs. Langmuir 27:6950–6961. doi:10.1021/la200499p
Mohod SM, Bodhankar SL (2013) Antiulcer activity of aqueous
extract of leaves of Madhuca indica J. F. Gmel against naproxen
induced gastric mucosal injury in rats. J Acute Dis 2:127–133.
doi:10.1016/S2221-6189(13)60112-2
Musumba C, Pritchard DM, Pirmohamed M (2009) Review article:
cellular and molecular mechanisms of NSAID-induced peptic
ulcers. Aliment Pharmacol Ther 30:517–531. doi:10.1111/j.
1365-2036.2009.04086.x
Naito Y, Yoshikawa T, Yagi N et al (2001) Effects of polaprezinc on
lipid peroxidation, neutrophil accumulation, and TNF-a expres-
sion in rats with aspirin-induced gastric mucosal injury. Dig Dis
Sci 46:845–851. doi:10.1023/A:1010716804594
Opoka W, Adamek D, Plonka M et al (2010) Importance of luminal
and mucosal zinc in the mechanism of experimental gastric ulcer
healing. J Physiol Pharmacol 61:581–591
Park SC, Chun HJ, Kang CD, Sul D (2011) Prevention and
management of non-steroidal anti-inflammatory drugs-induced
small intestinal injury. World J Gastroenterol 17:4647–4653.
doi:10.3748/wjg.v17.i42.4647
Patrono C, Rocca B (2009) Nonsteroidal antiinflammatory drugs:
past, present and future. Pharmacol Res 59:285–289. doi:10.
1016/j.phrs.2009.01.011
Powell SR (2000) Zinc and health: current status and future
directions. the antioxidant properties of zinc. J Nutr
130:1488–1492
Santos LH, Feres CAO, Melo FH et al (2004) Anti-inflammatory,
antinociceptive and ulcerogenic activity of a zinc-diclofenac
complex in rats. Braz J Med Biol Res 37:1205–1213. doi:10.
1590/S0100-879X2004000800011
Sharma J, Singla AK, Dhawan S (2003) Zinc–naproxen complex:
synthesis, physicochemical and biological evaluation. Int J
Pharm 260:217–227. doi:10.1016/S0378-5173(03)00251-5
Shimada T, Watanabe N, Ohtsuka Y et al (1999) Polaprezinc down-
regulates proinflammatory cytokine-induced nuclear factor-kap-
paB activation and interleukin-8 expression in gastric epithelial
cells. J Pharmacol Exp Ther 291:345–352
Singla AK, Wadhwa H (1995) Zinc-indomethacin complex: synthe-
sis, physicochemical and biological evaluation in the rat. Int J
Pharm 120:145–155. doi:10.1016/0378-5173(94)00370-K
Sivalingam N, Pichandi S, Chapla A et al (2011) Zinc protects against
indomethacin-induced damage in the rat small intestine. Eur J
Pharmacol 654:106–116. doi:10.1016/j.ejphar.2010.12.014
Skeljo MV, Giraud AS, Yeomans ND (1992) Adaptation of rat gastric
mucosa to repeated doses of non-salicylate non-steroidal anti-
inflammatory drugs. J Gastroenterol Hepatol 7:586–590. doi:10.
1128/JCM.39.5.1845
Skeljo MV, Cook GA, Elliott SL et al (1996) Gastric mucosal
adaptation to diclofenac injury. Dig Dis Sci 41:32–39
Skrovanek S (2014) Zinc and gastrointestinal disease. World J
Gastrointest Pathophysiol 5:496. doi:10.4291/wjgp.v5.i4.496
Smith AF, Loo G (2012) Upregulation of haeme oxygenase-1 by zinc
in HCT-116 cells. Free Radic Res 46:1099–1107. doi:10.3109/
10715762.2012.690872
Sostres C, Gargallo CJ, Arroyo MT, Lanas A (2010) Adverse effects
of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and
coxibs) on upper gastrointestinal tract. Best Pract Res Clin
Gastroenterol 24:121–132. doi:10.1016/j.bpg.2009.11.005
Tagliati CA, Kimura E, Nothenberg MS et al (1999) Pharmacokinetic
profile and adverse gastric effect of zinc-piroxicam in rats. Gen
Pharmacol 33:67–71. doi:10.1016/S0306-3623(98)00267-5
Tapiero H, Tew KD (2003) Trace elements in human physiology and
pathology: zinc and metallothioneins. Biomed Pharmacother
57:399–411. doi:10.1016/S0753-3322(03)00081-7
Ueda K, Ueyama T, Oka M et al (2009) Polaprezinc (zinc L-
carnosine) is a potent inducer of anti-oxidative stress enzyme,
heme oxygenase (HO)-1—a new mechanism of gastric mucosal
protection. J Pharmacol Sci 110:285–294
Wallace JL (2008) Prostaglandins, NSAIDs, and gastric mucosal
protection: why doesn’t the stomach digest itself? Physiol Rev
88:1547–1565. doi:10.1152/physrev.00004.2008
Watanabe T, Arakawa T, Fukuda T et al (1995) Zinc deficiency
delays gastric ulcer healing in rats. Dig Dis Sci 40:1340–1344
Watanabe T, Higuchi K, Tanigawa T et al (2002) Mechanisms of
peptic ulcer recurrence: role of inflammation. Inflammopharma-
cology 10:291–302. doi:10.1163/156856002321544765
Winter CA, Risley EA, Nuss GW (1962) Carrageenin-induced edema
in hind paw of the rat as an assay for antiiflammatory drugs. Exp
Biol Med 111:544–547. doi:10.3181/00379727-111-27849
Yasui K, Baba A (2006) Therapeutic potential of superoxide
dismutase (SOD) for resolution of inflammation. Inflamm Res
55:359–363. doi:10.1007/s00011-006-5195-y
Yasui K, Kobayashi N, Yamazaki T et al (2005) Superoxide
dismutase (SOD) as a potential inhibitory mediator of inflam-
mation via neutrophil apoptosis. Free Radic Res 39:755–762.
doi:10.1080/10715760500104066
Zhao Y, Tan Y, Dai J et al (2011) Exacerbation of diabetes-induced
testicular apoptosis by zinc deficiency is most likely associated
with oxidative stress, p38 MAPK activation, and p53 activation
in mice. Toxicol Lett 200:100–106. doi:10.1016/j.toxlet.2010.11.
001
Evaluation of anti-inflammatory and ulcerogenic potential of zinc–ibuprofen and zinc… 663
123
